Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609336 · ClinicalTrials.gov registry record · Phase 2
Perioperative Therapy for Resectable Pancreatic Cancer
A Phase 2 study of Adenocarcinoma of the Pancreas and Stage IIA Pancreatic Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00609336: Completed Phase 2 study of Adenocarcinoma of the Pancreas and Stage IIA Pancreatic Cancer, sponsored by University of Washington.
NCT00609336 is a Phase 2 study of Adenocarcinoma of the Pancreas and Stage IIA Pancreatic Cancer that has completed, run by University of Washington. The registered enrollment target is 35 participants, below the 86-participant average among 10 other Adenocarcinoma of the Pancreas trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00609336, a Phase 2 study of Adenocarcinoma of the Pancreas and Stage IIA Pancreatic Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, capecitabine, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy, such as IMRT, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving more than one drug (combination chemotherapy) together with intensity-modulated radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.
Primary Outcome
Time at which Kaplan-Meier estimate of overall survival drops below 50%
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG oxaliplatin
- RADIATION intensity-modulated radiation therapy
- DRUG capecitabine
- DRUG gemcitabine hydrochloride
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
What the finished NCT00609336 record still lists
NCT00609336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 86-participant average among 10 other Adenocarcinoma of the Pancreas trials with a reported enrollment target (59% lower).
The record links to 5 conditions, with Adenocarcinoma of the Pancreas appearing as the primary indexed condition, and to 5 interventions - of which docetaxel is the first listed.
NCT00609336 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00609336 about?
NCT00609336 is a clinical study titled "Perioperative Therapy for Resectable Pancreatic Cancer". This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docet...
What is the current status of trial NCT00609336?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-01. Estimated completion is 2016-12.
What conditions does trial NCT00609336 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Pancreas, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer.
What interventions are being tested in trial NCT00609336?
The interventions under investigation include: docetaxel (DRUG), oxaliplatin (DRUG), intensity-modulated radiation therapy (RADIATION), capecitabine (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00609336?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00609336 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Pancreas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00609336's enrollment target sits among peer trials
35 6th of 10 higher than 5 of 10 other Adenocarcinoma of the Pancreas trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Pancreas trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
COMPLETED · Phase 2
-
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia